BARCELONA – A new look at aducanumab’s phase I study data has reinforced the developer’s confidence that its newly launched phase III trials are targeting the right group: patients with very early...

Field of Interest: Geriatrics

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness